SEC Form 4 · accession 0001661181-18-000032
Organogenesis Holdings Inc. · ORGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary S. Gillheeney
Officer — President and CEO · Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 7:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001661181
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $1.70 | Dec 10, 2018 | A | 397,900 | A | — | Jul 1, 2019 | Common Stock | 397,900 | 397,900 | D |
| Stock Option (Right to Buy)F4,F3 | $0.99 | Dec 10, 2018 | A | 704,410 | A | — | Jul 25, 2023 | Common Stock | 704,410 | 704,410 | D |
| Stock Option (Right to Buy)F5,F1 | $0.99 | Dec 10, 2018 | A | 664,804 | A | — | Aug 21, 2024 | Common Stock | 664,804 | 664,804 | D |
| Stock Option (Right to Buy)F7,F6 | $0.99 | Dec 10, 2018 | A | 1,637,631 | A | — | Dec 8, 2024 | Common Stock | 1,637,631 | 1,637,631 | D |
Explanation of responses
- F1100% of the shares subject to this option are fully vested and exercisable.
- F2Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 196,010 shares of common stock of Organogenesis for $3.45 per share.
- F3The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2016.
- F4Received in connection with the Merger in exchange for an option to acquire 347,000 shares of common stock of Organogenesis for $2.00 per share.
- F5Received in connection with the Merger in exchange for an option to acquire 327,490 shares of common stock of Organogenesis for $2.00 per share.
- F6The shares underlying the option vested or shall vest 20% annually beginning on December 8, 2015.
- F7Received in connection with the Merger in exchange for an option to acquire 806,715 shares of common stock of Organogenesis for $2.00 per share.